Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are:
- to establish the safety of subcutaneous administration of ceftriaxone at different
concentrations, with and without HYLENEX recombinant, and to determine the maximum
tolerated concentration;
- and to establish the pharmacokinetic comparability of subcutaneous administration of
ceftriaxone with HYLENEX recombinant to subcutaneous administration without HYLENEX
recombinant and to IV administration.